CD274 and non-small cell lung carcinoma: In the case of squamous cell cancer, in contrast to non-squamous NSCLC, mutation load but not PD-L1 expression may be predictive of outcome.21,37,38 Ongoing phase-1 and phase-2 studies with checkpoint inhibitors combined with TKI will be critical to determine the safety and efficacy of this therapeutic strategy.